Types and risk factors Understanding gallstone types helps predict risk and management strategies: How Mounjaro affects gallbladder function Clinical trial data on gallbladder events The SURMOUNT clinical trials provide comprehensive safety data on Mounjaros gallbladder effects 1 : SURMOUNT-1 findings: Gallbladder-related adverse events: 0.6% (Mounjaro) vs 0% (placebo) Most events were cholelithiasis (gallstones) or cholecystitis Higher doses (10 mg, 15 mg) showed a slightly higher risk than 5 mg Most events occurred within the first 20 weeks of treatment Severity of events: Mild to moderate: 85% of cases Severe: 15% of cases Led to treatment discontinuation: 2 cm) Porcelain gallbladder Concurrent liver disease Pre-treatment screening NICE guidelines dont mandate gallbladder screening before starting GLP-1 medications 5 , but consider assessment if: High-risk patients: Previous gallstone symptoms Multiple risk factors present Strong family history Previous rapid weight loss attempts Screening options: Detailed history and examination Liver function tests (may be elevated with gallstones) Ultrasound scan if clinically indicated Risk stratification *Monitoring frequency represents expert practice suggestions rather than mandated protocol
They should not be treated as equivalent
it's helping your skin act younger
Fatigue and nausea for the first 48 hours after the weekly injection, increased anxiety and panic attacks, and constipation were common
Lee SA, Kim YR, Yang EJ, Kwon EJ, Kim SH, Kang SH, Park DB, Oh BC, Kim J, Heo ST, Koh G, Lee DH (2013) CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus
